Kristin DeSilva

Kristin DeSilva

Auto-generated profile, based on publicly available information

Kristin DeSilva

Massachusetts General Hospital and Harvard Medical School Boston Massachusetts

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
KDKristin M. D’sIlva
Kristin M. D’sIlva
AJApril Jorge
April Jorge
ACAndrew Cohen
Andrew Cohen
NMNatalie McCormick
Natalie McCormick
YZYuqing Zhang
Yuqing Zhang
HCHyon Choi
Hyon Choi
Objective: Patients with systemic autoimmune rheumatic diseases (ARDs) continue to be concerned about risks of severe coronavirus disease 2019 (COVID‐19) outcomes. This study was undertaken to evaluate the risks of severe outcomes in COVID‐19 patients with systemic ARDs compared to COVID‐19 patients without systemic ARDs.Methods: Using a large multicenter electronic health record network, we conducted a comparative cohort study of patients with systemic ARDs diagnosed as having COVID‐19 (identified by diagnostic code or positive molecular test result) compared to patients with COVID‐19 who did not have systemic ARDs, matched for age, sex, race/ethnicity, and body mass index (primary matched model) and additionally matched for comorbidities and health care utilization (extended matched model). Thirty‐day outcomes were assessed, including hospitalization, intensive care unit (ICU) admission, mechanical ventilation, acute renal failure requiring renal replacement therapy, ischemic stroke, venous thromboembolism, and death.Results: We initially identified 2,379 COVID‐19 patients with systemic ARDs (mean age 58 years; 79% female) and 142,750 comparators (mean age 47 years; 54% female). In the primary matched model (2,379 patients with systemic ARDs and 2,379 matched comparators with COVID‐19 without systemic ARDs), patients with systemic ARDs had a significantly higher risk of hospitalization (relative risk [RR] 1.14 [95% confidence interval (95% CI) 1.03–1.26]), ICU admission (RR 1.32 [95% CI 1.03–1.68]), acute renal failure (RR 1.81 [95% CI 1.07–3.07]), and venous thromboembolism (RR 1.74 [95% CI 1.23–2.45]) versus comparators but did not have a significantly higher risk of mechanical ventilation or death. In the extended model, all risks were largely attenuated, except for the risk of venous thromboembolism (RR 1.60 [95% CI 1.14–2.25]).Conclusion: Our findings indicate that COVID‐19 patients with systemic ARDs may be at a higher risk of hospitalization, ICU admission, acute renal failure, and venous thromboembolism when compared to COVID‐19 patients without systemic ARDs. These risks may be largely mediated by comorbidities, except for the risk of venous thromboembolism.

1 December 2019 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
CLCianna Leatherwood
Cianna Leatherwood
CSCameron B. Speyer
Cameron B. Speyer
CFCandace H. Feldman
Candace H. Feldman
KDKristin D'SIlva
Kristin D'SIlva
JGJosé A Gómez-Puerta
José A Gómez-Puerta
KCKaren H. Costenbader
Karen H. Costenbader

1 May 2021 in Annals of the Rheumatic Diseases
Verified
Journal Article
Closed access
NSNaomi Serling-Boyd
Naomi Serling-Boyd
KDKristin M D’sIlva
Kristin M D’sIlva
THTiffany Yt Hsu
Tiffany Yt Hsu
RWRachel Wallwork
Rachel Wallwork
XFXiaoqing Fu
Xiaoqing Fu
ZWZachary S Wallace
Zachary S Wallace
In earlier studies, patients with rheumatic and musculoskeletal disease (RMD) who got infected with COVID-19 had a higher risk of mechanical ventilation than comparators. We sought to determine COVID-19 outcomes among patients with RMD 6 months into the pandemic. We conducted a cohort study at Mass General Brigham in Boston, Massachusetts, of patients with RMD matched to up to five comparators by age, sex and COVID-19 diagnosis date (between 30 January 2020 and 16 July 2020) and followed until last encounter or 18 August 2020. COVID-19 outcomes were compared using Cox regression. Risk of mechanical ventilation was compared in an early versus a recent cohort of patients with RMD. We identified 143 patients with RMD and with COVID-19 (mean age 60 years; 76% female individuals) and 688 comparators (mean age 59 years; 76% female individuals). There were no significantly higher adjusted risks of hospitalisation (HR: 0.87, 95% CI: 0.68–1.11), intensive care unit admission (HR: 1.27, 95% CI: 0.86–1.86), or mortality (HR: 1.02, 95% CI: 0.53–1.95) in patients with RMD versus comparators. There was a trend towards a higher risk of mechanical ventilation in the RMD cohort versus comparators, although not statistically significant (adjusted HR: 1.51, 95% CI: 0.93–2.44). There was a trend towards improvement in mechanical ventilation risk in the recent versus early RMD cohort (10% vs 19%, adjusted HR: 0.44, 95% CI: 0.17–1.12). Patients with RMD and comparators had similar risks of poor COVID-19 outcomes after adjusting for race, smoking and comorbidities. The higher risk of mechanical ventilation in the early RMD cohort was no longer detected in a recent cohort, suggesting improved management over time.

1 March 2015 in American Journal of Kidney Diseases
Verified
Journal Article
Closed access
PDF file
JIJula K. Inrig
Jula K. Inrig
CMChristopher Molina
Christopher Molina
KDKristin D’sIlva
Kristin D’sIlva
CKCatherine Kim
Catherine Kim
PBPeter Van Buren
Peter Van Buren
RTRobert Toto
Robert Toto

1 December 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MMMeenalakshmi M. Mariappan
Meenalakshmi M. Mariappan
SPSanjay Prasad
Sanjay Prasad
KDKristin D'Silva
Kristin D'Silva
ECEsteban Cedillo
Esteban Cedillo
KSKavithalakshmi Sataranatarajan
Kavithalakshmi Sataranatarajan
BKBalakuntalam S. Kasinath
Balakuntalam S. Kasinath
Increase in protein synthesis contributes to kidney hypertrophy and matrix protein accumulation in diabetes. We have previously shown that high glucose-induced matrix protein synthesis is associated with inactivation of glycogen synthase kinase 3β (GSK3β) in renal cells and in the kidneys of diabetic mice. We tested whether activation of GSK3β by sodium nitroprusside (SNP) mitigates kidney injury in diabetes. Studies in kidney-proximal tubular epithelial cells showed that SNP abrogated high glucose-induced laminin increment by stimulating GSK3β and inhibiting Akt, mTORC1, and events in mRNA translation regulated by mTORC1 and ERK. NONOate, an NO donor, also activated GSK3β, indicating that NO may mediate SNP stimulation of GSK3β. SNP administered for 3 weeks to mice with streptozotocin-induced type 1 diabetes ameliorated kidney hypertrophy, accumulation of matrix proteins, and albuminuria without changing blood glucose levels. Signaling studies showed that diabetes caused inactivation of GSK3β by activation of Src, Pyk2, Akt, and ERK; GSK3β inhibition activated mTORC1 and downstream events in mRNA translation in the kidney cortex. These reactions were abrogated by SNP. We conclude that activation of GSK3β by SNP ameliorates kidney injury induced by diabetes.

1 January 2011 in American Journal of Physiology-Renal Physiology
Verified
Journal Article
Open access
PDF file
MMMeenalakshmi M. Mariappan
Meenalakshmi M. Mariappan
KDKristin D'Silva
Kristin D'Silva
MLMyung Ja Lee
Myung Ja Lee
KSKavithalakshmi Sataranatarajan
Kavithalakshmi Sataranatarajan
JBJeffrey L. Barnes
Jeffrey L. Barnes
BKBalakuntalam S. Kasinath
Balakuntalam S. Kasinath
Diabetes promotes protein synthesis to induce kidney hypertrophy and increase renal matrix proteins. Increased capacity for mRNA translation by way of ribosomal biogenesis facilitates sustained stimulation of protein synthesis. We tested the hypothesis that high glucose induces ribosomal biogenesis as indicated by an increase in rRNA synthesis in the setting of augmented protein synthesis. High glucose (30 mM) increased global protein synthesis, expression of matrix proteins, laminin γ1 and fibronectin, and rDNA transcription in glomerular epithelial cells (GECs) compared with 5 mM glucose. High glucose induced Ser388 phosphorylation of upstream binding factor (UBF), an rDNA transcription factor, along with increased phosphorylation of Erk and p70S6 kinase. Inactivation of Erk and p70S6 kinase either by their respective chemical inhibitors or by expression of their inactive mutant constructs blocked high-glucose-induced UBF phosphorylation. High glucose reduced nuclear content of p19ARF and promoted dissolution of inactive UBF-p19ARF complex. High glucose also promoted association of UBF with RPA194, a subunit of RNA polymerase I. Inhibition of Erk, p70S6 kinase, and UBF1 by transfecting GECs with their respective inactive mutants abolished laminin γ1 synthesis, protein synthesis, and rDNA transcription. Renal cortex from type 1 diabetic rats and type 2 diabetic db/db mice showed increased phosphorylation of UBF, Erk, and p70S6 kinase coinciding with renal hypertrophy and onset of matrix accumulation. Our data suggest that augmented ribosome biogenesis occurs in an UBF-dependent manner during increased protein synthesis induced by high glucose in the GECs that correlates with UBF activation and renal hypertrophy in rodents with type 1 and type 2 diabetes.